Structure Therapeutics Inc.
GPCR · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $59 | $55 | $43 | $33 |
| G&A Expenses | $15 | $16 | $13 | $14 |
| SG&A Expenses | $15 | $16 | $13 | $14 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $74 | $70 | $56 | $47 |
| Operating Income | -$74 | -$70 | -$56 | -$47 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $8 | $9 | $10 | $11 |
| Pre-Tax Income | -$66 | -$62 | -$47 | -$36 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$66 | -$62 | -$47 | -$36 |
| % Margin | – | – | – | – |
| EPS | -1.11 | -1.08 | -0.81 | -0.63 |
| % Growth | -2.8% | -33.3% | -28.6% | – |
| EPS Diluted | -1.11 | -1.08 | -0.81 | -0.63 |
| Weighted Avg Shares Out | 58 | 58 | 57 | 57 |
| Weighted Avg Shares Out Dil | 58 | 58 | 57 | 57 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $9 | $10 | $11 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$65 | -$70 | -$56 | -$47 |
| % Margin | – | – | – | – |